粪便免疫化学检测结直肠癌筛查项目的参与率、阳性率与检出率系统综述
系统综述与荟萃分析纳入24项研究,评估组织性FIT结直肠癌筛查项目的参与模式及每轮参与率、FIT阳性率和肿瘤检出率。结果显示约47.1%为持续筛查者,30.3%从未参与;首轮FIT阳性率及结直肠癌、进展期腺瘤和腺瘤的阳性预测值最高,至第三至四轮趋于稳定。
要点
- 持续筛查者占47.1%,间歇筛查者22.7%,从未参与者30.3%。
- 首轮至第四轮每轮参与率分别为51.3%、56.7%、56.9%、56.5%。
- FIT阳性率及结直肠癌、进展期腺瘤阳性预测值首轮最高,第三至四轮趋稳。
核心结论
- 组织性FIT结直肠癌筛查项目中近半数人持续参与,约三分之一从未参与。
- FIT阳性率及结直肠癌、进展期腺瘤和腺瘤的阳性预测值首轮最高,可能在第三至四轮达到临床相关稳态。
研究设计与样本
- 系统综述与荟萃分析,系统检索PubMed、Embase和Cochrane数据库,最终纳入24项研究。
主要发现
- 持续筛查者占47.1%(标准差11.6%),间歇筛查者占22.7%(标准差4.7%),从未参与者占30.3%(标准差12.2%)。
- 首轮至第四轮每轮参与率分别为51.3%(95%CI 37.4%-65.3%)、56.7%(95%CI 41.3%-72.2%)、56.9%(95%CI 38.7%-75.3%)、56.5%(95%CI 44%-68.6%)。
- 首轮至第四轮FIT阳性率分别为6.6%(95%CI 5.9%-7.3%)、5.6%(95%CI 4.6%-6.6%)、5.3%(95%CI 4.0%-6.6%)、5.3%(95%CI 3.7%-6.9%)。
- 首轮至第四轮结直肠癌阳性预测值分别为5.8%(95%CI 4.1%-7.4%)、3.3%(95%CI 2.3%-4.3%)、2.9%(95%CI 2.2%-3.7%)、2.5%(95%CI 1.4%-3.5%)。
- 首轮至第四轮进展期腺瘤阳性预测值分别为32.8%(95%CI 23.5%-42.0%)、28.3%(95%CI 21.8%-34.7%)、22.7%(95%CI 16.5%-28.9%)、23%(95%CI 10.1%-35.9%)。
临床怎么用
- 临床应关注FIT筛查项目的长期参与率,针对从未参与和间歇参与人群加强宣教与随访。
- 首轮FIT阳性预测值较高,后续轮次趋于稳定,解读结果时需考虑筛查轮次的影响。
局限性
- 纳入研究间参与率和阳性率存在异质性,部分结果标准差较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fecal immunochemical testing (FIT), the most common colorectal cancer (CRC) screening modality worldwide, requires programmatic participation over decades. We performed a systematic review and meta-analysis to ascertain overall adherence patterns, per-round participation, FIT positivity, and neoplasia detection rates in organized FIT-based screening programs, contrasting initial vs subsequent screening rounds. METHODS: We systematically searched the PubMed, Embase, and Cochrane databases. Adherence patterns were defined as consistent screeners (all rounds), intermittent screeners, and never attendants. Per-round participation, FIT positivity, and positive predictive values (PPVs) for CRC, advanced adenoma (AA), and adenoma were determined overall and for consistent screeners. Subgroup analyses were performed by screening periodicity and FIT positivity cutoff. RESULTS: Of 4414 candidate studies, 24 were included. Adherence patterns were: 47.1% (standard deviation [SD], 11.6%) consistent screeners, 22.7% (SD, 4.7%) intermittent screeners, and 30.3% (SD, 12.2%) never attendants. Overall pooled results from the first through fourth rounds showed per-round participation of 51.3% (95% confidence interval [CI], 37.4%-65.3%); 56.7% (95% CI, 41.3%-72.2%), 56.9% (95% CI, 38.7%-75.3%), and 56.5% (95% CI, 44%-68.6%); FIT positivity of 6.6% (95% CI, 5.9%-7.3%), 5.6% (95% CI, 4.6%-6.6%), 5.3% (95% CI, 4.0%-6.6%), and 5.3% (3.7%-6.9%); CRC PPV of 5.8% (95% CI, 4.1%-7.4%), 3.3% (95% CI, 2.3%-4.3%), 2.9% (95% CI, 2.2%-3.7%), and 2.5% (95% CI, 1.4%-3.5%); AA PPV of 32.8% (95% CI, 23.5%-42.0%), 28.3% (95% CI, 21.8%-34.7%), 22.7% (95% CI, 16.5%-28.9%), and 23% (95% CI, 10.1%-35.9%); and adenoma PPV of 48.6% (95% CI, 45.8%-51.4%), 46.2% (95% CI, 42.4%-50.1%), 48.7% (95% CI, 43.9%-53.6%), and 44.6% (95% CI, 38.2%-51.0%), respectively. Similar trends were observed for consistent screeners and for biennial FIT with 20 μg Hb/g feces positivity cutoff. CONCLUSIONS: Organized FIT-based CRC screening programs achieve consistent participation in nearly one-half of persons and no participation in approximately one-third. FIT-positivity and yields for CRC, AA, and adenoma are highest in the first round and may stabilize at clinically relevant steady states at the third to fourth rounds.
引用
- Baile-Maxía S, Pimienta M, Sánchez-Ardila C, et al. Systematic Review of Participation, Positivity, and Yield Over Time in Fecal Immunochemical Test-Based Organized Colorectal Cancer Screening Programs. Clin Gastroenterol Hepatol. 2026. PMID: 41724209. doi:10.1016/j.cgh.2026.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。